Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Therapeutic Targets for Diabetes and Associated Complications
share announcement

Therapeutic Targets for Diabetes and Associated Complications

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 4074

Special Issue Editor

Dr. Md Badrul Alam

E-Mail Website
Guest Editor
Department of Food Biotechnology, College of Life Science, Kyungpook National University, Daegu, Republic of Korea
Interests: novel targets for treatment of diabetes mellitus and its complications; the functions and roles of diabetic biomarkers; new pharmacophores and pharmacology of targeted molecules; novel small synthetic molecules inhibitors; value-added foods

Special Issue Information

Dear Colleagues,

Diabetes mellitus (DM) is a chronic condition characterized by hyperglycemia. This continual increase in glucose levels causes oxidative damage, which can trigger the development of several chronic ailments, including renal disease, blindness, heart attacks, strokes, neuropathy, and skin and foot disorders. These effects have been connected, either directly or indirectly, to diabetes' high rates of morbidity and mortality. Diabetes and its consequences can be diagnosed and prognosed with the help of biomarkers and intracellular and extracellular signaling pathways. Therefore, it is crucial to develop novel and improved therapeutic targets for treating this condition, as well as specific tiny molecules that impact these targets.

This Special Issue invites authors to contribute original research and review articles that present cutting-edge discoveries of biomarkers and cellular and molecular mechanisms engaged in diabetes mellitus and its consequences.

Dr. Md Badrul Alam
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel targets for the treatment of diabetes mellitus and its complications
  • the functions and roles of diabetic biomarkers
  • new pharmacophores and pharmacology of targeted molecules
  • novel small synthetic molecules inhibitors
  • value-added foods

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

29 pages, 9089 KiB  
Article
Efficiency of Bone Marrow-Derived Mesenchymal Stem Cells and Hesperetin in the Treatment of Streptozotocin-Induced Type 1 Diabetes in Wistar Rats
by Osama M. Ahmed, Ablaa S. Saleh, Eman A. Ahmed, Mohammed M. Ghoneim, Hasnaa Ali Ebrahim, Mohamed A. Abdelgawad and Mohammed Abdel-Gabbar
Pharmaceuticals 2023, 16(6), 859; https://doi.org/10.3390/ph16060859 - 08 Jun 2023
Cited by 2 | Viewed by 2142
Abstract
Type 1 diabetes mellitus (T1DM) was established to be ameliorated by islet transplantation, but the shortage of the transplanted human islet tissue and the use of immunosuppressive drugs to inhibit the rejection of allogeneic grafts make this type of therapy is limited. Nowadays, [...] Read more.
Type 1 diabetes mellitus (T1DM) was established to be ameliorated by islet transplantation, but the shortage of the transplanted human islet tissue and the use of immunosuppressive drugs to inhibit the rejection of allogeneic grafts make this type of therapy is limited. Nowadays, therapy with stem cells is one of the most promising future treatments. This kind of therapy could have a profound impact on both replacement, as well as regenerative therapies, to improve or even cure various disorders, including diabetes mellitus. Flavonoids have also been shown to possess anti-diabetic effects. Thus, this study aims to evaluate the effectiveness of the bone marrow-derived mesenchymal stem cells (BM-MSCs) and hesperetin in the treatment of a T1DM rat model. T1DM was induced in male Wistar rats that had been starved for 16 h via intraperitoneal injection of STZ at a dose of 40 mg/kg body weight (b.wt.). After 10 days of STZ injection, the diabetic rats were allocated into four groups. The first diabetic animal group was considered a diabetic control, while the other three diabetic animal groups were treated for six weeks, respectively, with hesperetin (given orally at a dose of 20 mg/kg b.wt.), BM-MSCs (injected intravenously at a dose of 1 × 106 cells/rat/week), and their combination (hesperetin and BM-MSCs). The use of hesperetin and BM-MSCs in the treatment of STZ-induced diabetic animals significantly improved the glycemic state, serum fructosamine, insulin and C-peptide levels, liver glycogen content, glycogen phosphorylase, glucose-6-phosphatase activities, hepatic oxidative stress, and mRNA expressions of NF-κB, IL-1β, IL-10, P53, and Bcl-2 in pancreatic tissue. The study suggested the therapy with both hesperetin and BM-MSCs produced marked antihyperglycemic effects, which may be mediated via their potencies to ameliorate pancreatic islet architecture and insulin secretory response, as well as to decrease hepatic glucose output in diabetic animals. The improvement effects of hesperetin and BM-MSCs on the pancreatic islets of diabetic rats may be mediated via their antioxidant, anti-inflammatory, and antiapoptotic actions. Full article
(This article belongs to the Special Issue Therapeutic Targets for Diabetes and Associated Complications)
►▼ Show Figures

Figure 1

12 pages, 8861 KiB  
Article
The Effects of Prolonged Treatment with Cemtirestat on Bone Parameters Reflecting Bone Quality in Non-Diabetic and Streptozotocin-Induced Diabetic Rats
by Monika Martiniakova, Veronika Kovacova, Vladimira Mondockova, Karol Svik, Piotr Londzin, Joanna Folwarczna, Marta Soltesova Prnova, Milan Stefek and Radoslav Omelka
Pharmaceuticals 2023, 16(4), 628; https://doi.org/10.3390/ph16040628 - 21 Apr 2023
Cited by 3 | Viewed by 1592
Abstract
Cemtirestat, a bifunctional drug acting as an aldose reductase inhibitor with antioxidant ability, is considered a promising candidate for the treatment of diabetic neuropathy. Our study firstly examined the effects of prolonged cemtirestat treatment on bone parameters reflecting bone quality in non-diabetic rats [...] Read more.
Cemtirestat, a bifunctional drug acting as an aldose reductase inhibitor with antioxidant ability, is considered a promising candidate for the treatment of diabetic neuropathy. Our study firstly examined the effects of prolonged cemtirestat treatment on bone parameters reflecting bone quality in non-diabetic rats and rats with streptozotocin (STZ)-induced diabetes. Experimental animals were assigned to four groups: non-diabetic rats, non-diabetic rats treated with cemtirestat, diabetic rats, and diabetic rats treated with cemtirestat. Higher levels of plasma glucose, triglycerides, cholesterol, glycated hemoglobin, magnesium, reduced femoral weight and length, bone mineral density and content, parameters characterizing trabecular bone mass and microarchitecture, cortical microarchitecture and geometry, and bone mechanical properties were determined in STZ-induced diabetic versus non-diabetic rats. Treatment with cemtirestat did not affect all aforementioned parameters in non-diabetic animals, suggesting that this drug is safe. In diabetic rats, cemtirestat supplementation reduced plasma triglyceride levels, increased the Haversian canal area and slightly, but insignificantly, improved bone mineral content. Nevertheless, the insufficient effect of cemtirestat treatment on diabetic bone disease does not support its use in the therapy of this complication of type 1 diabetes mellitus. Full article
(This article belongs to the Special Issue Therapeutic Targets for Diabetes and Associated Complications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop